Treatment of medullary thyroid carcinoma by combined expression of suicide and interleukin-2 genes

Cancer Immunology Immunotherapy

Volumn 48, Issue 2-3, 1999, Pages 91-99

  Soler, M N ^a   Milhaud, G ^b   Lekmine, F ^a   Treilhou Lahille, F ^a   Klatzmann, D ^c   Lausson, S ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL LABELING; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION; GENE THERAPY; IMMUNOHISTOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; SUICIDE GENE; THYROID MEDULLARY CARCINOMA;

ANIMALS; ANTIVIRAL AGENTS; CARCINOMA, MEDULLARY; GANCICLOVIR; GENE THERAPY; HERPESVIRUS 1, HUMAN; INTERLEUKIN-2; RATS; RATS, INBRED STRAINS; T-LYMPHOCYTES; THYMIDINE KINASE; THYROID NEOPLASMS;

EID: 0033065777     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050552     Document Type: Article

References (44)

1. Baker PE, Gillis S, Smith KA (1979) Monoclonal cytolytic T-cell lines. J Exp Med 149:273
2. Barba D, Hardin J, Sadelain M, Gage FH (1994) Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci USA 91:4348
3. Beck C, Cayeux S, Lupton SD, Dorken B, Blankenstein T (1995) The thymidine kinase ganciclovir-mediated "suicide" effect is variable in different tumor cells. Hum Gene Ther 6:1525
4. Boorman GA, DeLellis RE (1983) C cell hyperplasia, adenoma, carcinoma, thyroid, rat. In: Jones TC (ed). Endocrine system. Springer, Berlin Heidelberg New-York, p 192
5. Bubenik J, Simova J, Jandlova T (1990) Immunotherapy of cancer using local administration of lymphoid cells expression IL-2 cDNA and constitutively producing IL-2. Immunol Lett 23:287
6. Caruso M, Panis Y, Gagandeep S, Houssin D, Salzmann JL, Klatzmann D (1993) Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci USA 90:7024
7. Caruso M, Salomon B, Zhang S, Brisson E, Clavel F, Lowy I, Klatzmann D (1995) Expression of a Tat-inductible herpes simplex virus-thymidine kinase gene protects acyclovir-treated CD4 cells from HIV-1 spread by conditional suicide and inhibition of reverse transcription. Virology 206:495
8. Chen SH, Chen XHL, Wang Y, Kosai KI, Finegold MJ, Rich SS, Woo SLC (1995) Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci USA 92:2577
9. Connor J, Baannerji R, Saito S, Heston W, Fair W, Gilboa E (1993) Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J Exp Med 177:1127
10. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM (1992) In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256:1550
11. Damoiseaux JGMC, Dopp EA, Calame W, Chao D, MacPherson GG (1994) Rat macrophage lysosomal membrane antigen recognized ky monoclonal antibody ED1. Immunology 83:140
12. Delisle MJ (1988) Surveillance au long cours des cancers médullaires de la thyroide. Ann Endocrinol 49:51
13. Elshami AA, Saavedra A, Zhang H, Kucharczuk JC, Spray DC, Fishman GI, Amin KM, Kaiser LR, Albelda SM (1996) Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase ganciclovir system in vitro. Gene Ther 3:85
14. Ezzedine ZD, Martuza RL, Platika D, Short MP, Malick A, Choi B, Breakefield XO (1991) Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol 3:608
15. Fearon EF, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B, Frost P (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60:397
16. Festing MF (1979) Inbred Strains. In: Baker, Russel, Weithbross (eds). The laboratory rat, vol 1. Biology and diseases. Academic Press, New York p 55
17. Pick J, Barker FG, Dazin P, Westphale EM, Beyer EC (1995) The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc Natl Acad Sci USA 92:11 071
18. Freeman SM, Addoud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, Abraham GN (1993) The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53:5274
19. Gagandeep S, Brew R, Green B, Chrismas SE, Klatzmann D, Poston GJ, Kinsella AR (1996) Prodrug-activated gene therapy: involvement of an immunological component in the "bystander effect". Cancer Gene Ther 3:83
20. Gansbacher B, Zier K, B. D, Cronin K, Bannerji R, Gilboa E (1990) Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172:1217
21. Gold R, Schmied M, Giegerich G, Breitschopf H, Hartung HP, Toyka KV, Lassmann H (1994) Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques. Lab Invest 71:219
22. Hall SJ, Mutchnik SE, Chen SH, Woo SLC, Thompson TC (1997) Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer. International J Cancer 70:183
23. Hamel W, Magnelli L, Chiarugi VP, Israel MA (1996) Herpes simplex virus thymidine kinase/ ganciclovir-mediated apoptotic death of bystander cells. Cancer Res 56:2697
24. Hoefnagel CA, Delprat CC, Zanin D, School JB van der (1988) New radionuclide tracers for the diagnosis and therapy of medullary thyroid carcinoma. Clin Nucl Med 13:159
25. Iwanuma Y, Kato K, Yagita H, Okumura K (1995) Induction of tumor-specific cytotoxic T lymphocytes and natural killer cells by tumor cells transfected with the interleukin-2 gene. Cancer Immunol Immunother 40:17
26. Kianmanesh AR, Perrin H, Panis Y, Fabre M, Nagy HJ, Houssin D, Klatzmann D (1997) A "distant" bystander effect of suicide gene therapy: regression of nontransduced tumors together with a distant transduced tumor. Human Gene Ther 8:1807
27. Lausson S, Volle GE, Bourges M, Pidoux E, Borrel C, Milhaud G, Moukhtar MS, Jullienne A, Treilhou-Lahille F (1995) Calcitonin secretion, C cell differentiation and proliferation, during the spontaneous development of murine medullary carcinoma (MTC). Virchows Arch [A] 426:611
28. Lausson S, Fournès B, Borrel C, Milhaud G, Treilhou-Lahille F (1996) Immune response against medullary thyroid carcinoma (MTC) induced by parental and/or interleukin-2-secreting MTC cells in a rat model of human familial medullary thyroid carcinoma. Cancer Immunol Immunother 43:116
29. Ley V, Langlade-Demoyen P, Kourilsky P, Larsson-Sciard EL (1991) Interleukin-2 dependent activation of tumor specific T lymphocytes in vivo. Eur J Immunol 21:581
30. Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H (1996) Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA 93:1831
31. Milhaud G, Tubiana M, Parmentier C, Coutris G (1968) Epithelioma de la thyroïde secrétant la thyrocalcitonine. C R Helod Séances Acad Sci Ser D Sci Nat 266:608
32. Moolten FL (1986) Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 46:5276
33. O'Malley BW, Cope KA, Chen SH, Li D, Schwartz MR, Woo SLC (1996) Combination gene therapy for oral cancer in a murine model. Cancer Res 56:1737
34. Ram Z, Culver KW, Walbridge S, Blaese RM, Oldfield EH (1993) In situ retroviral-mediated gene transfer for the treat-ment of brain tumors. Cancer Res 53:83
35. Roth C, Mir LM, Cressent M, Quitin-Colonna F, Ley V, Fradelizi D, Kourilsky (1992) Inhibition of tumor growth by histoincompatible cells expressing interleukin-2. Int Immunol 4:1429
36. Ruppert JM, Eggleston JC, deBustros A, Baylin SB (1986) Disseminated calcitonin-poor medullary carcinoma in a patient with calcitonin-rich primary tumor. 10:513
37. Saad MF, Guido JJ, Samaan NA (1983) Treatment of medullary carcinoma of the thyroid. J Clin Endocrinol Metab 57:124
38. Samejima Y, Meruelo D (1995) Bystander killing induces apoptosis and is inhibited by forskolin. Gene Ther 2:50
39. Vieweg J, Rosenthal F, Bannerji R, Heston WDW, Fair WR, Gansbacher B, Gilboa E (1994) Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res 54:1760
40. Vile RG, Nelson JA, Castelden S, Chong H, Hart IR (1994) Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 54:6228
41. Vile RG, Castleden S, Camplejohn R, Upton C, Chong H (1997) Generation of an anti-tumour response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int J Cancer 71:267
42. Zeitinoglu FS, DeLellis RE, Gagel RF, Wolfe HJ, Tashjian AH (1980) Establishment of a calcitonin-producing rat medullary thyroid carcinoma cell line. I. Morphological studies of the tumor and cells in culture. Endocrinology 107:509
43. Zhang L, Wikenheiser KA, Whitsett JA (1997) Limitations of retrovirus-mediated HSV-tk gene transfer to pulmonary adenocarcinoma cells in vitro and in vivo. Hum Gene Ther 8:563
44. Zhang R, Minemura, De Groot LJ (1998) Immunotherapy for medullary thyroid carcinoma by a replication-defective adenovirus transducing murine interleukin-2. Endocrinology 139:601